Verrica Pharmaceuticals Stock In The News

VRCA Stock  USD 6.14  0.45  6.83%   
Our overall analysis of Verrica Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Verrica Pharmaceuticals. The specific impact of Verrica Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Verrica Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Verrica Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Verrica Pharmaceuticals Backtesting and Verrica Pharmaceuticals Hype Analysis.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.

Verrica Pharmaceuticals Today Top News and Investor Outlook

seekingalpha News
Verrica Pharmaceuticals Non-GAAP EPS of $0.25 beats by $1.08, revenue of $12.7M
https://seekingalpha.com/news/4484205-verrica-pharmaceuticals-non-gaap-eps-of-0_25-beats-by-1_08-revenue-of-12_7m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Neutral
Macroaxis News: globenewswire.com
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
https://www.globenewswire.com/news-release/2025/08/12/3132093/0/en/Verrica-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html
 Neutral
Yahoo News
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
https://finance.yahoo.com/news/soleno-therapeutics-inc-slno-reports-211002515.html
 Bullish
Macroaxis News: globenewswire.com
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
https://www.globenewswire.com/news-release/2025/08/06/3128178/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-2025-Financial-Results-and-Provide-a-Corporate-Update-on-August-12-2025.html
 Bullish
Investing News at Macroaxis
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales
https://www.investing.com/news/company-news/verrica-pharmaceuticals-reports-328-quarterly-growth-in-ycanth-sales-93CH-4127919
 Bullish
Yahoo News
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
https://finance.yahoo.com/news/verrica-pharmaceuticals-reports-quarterly-2025-200500681.html
 Neutral
Macroaxis News: globenewswire.com
Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
https://www.globenewswire.com/news-release/2025/04/30/3071264/0/en/Verrica-Pharmaceuticals-to-Participate-in-the-Citizens-Life-Sciences-Conference-in-New-York.html
 Bullish
Macroaxis News: globenewswire.com
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
https://www.globenewswire.com/news-release/2025/03/11/3040993/0/en/Verrica-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html
 Neutral
Macroaxis News: globenewswire.com
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
https://www.globenewswire.com/news-release/2025/02/25/3032424/0/en/Verrica-Pharmaceuticals-to-Participate-in-the-TD-Cowen-45th-Annual-Health-Care-Conference-in-Boston.html
 Bullish
Macroaxis News: globenewswire.com
Verrica Pharmaceuticals Announces Presen...
https://www.globenewswire.com/news-release/2025/01/21/3012498/0/en/Verrica-Pharmaceuticals-Announces-Presentation-of-Three-Posters-Featuring-Positive-Preliminary-Topline-Results-of-VP-315-for-the-Treatment-of-Basal-Cell-Carcinoma-at-the-2025-Winte.html
 Neutral

Verrica Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Verrica and other traded companies coverage with news coverage. We help investors stay connected with Verrica headlines for the 14th of August 2025 to make an informed investment decision based on correlating the impacts of news items on Verrica Stock performance. Please note that trading solely based on the Verrica Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Verrica Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Verrica Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Verrica Pharmaceuticals noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Verrica Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Verrica Pharmaceuticals' short interest history, or implied volatility extrapolated from Verrica Pharmaceuticals options trading.
When determining whether Verrica Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verrica Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verrica Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verrica Pharmaceuticals Stock:
Check out Verrica Pharmaceuticals Backtesting and Verrica Pharmaceuticals Hype Analysis.
For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.40)
Revenue Per Share
1.124
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.63)
Return On Equity
(15.47)
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.